Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract
View Patent ↗A composition for treatment of bacterial infections of the eye is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme. The carrier for delivering at least one lytic enzyme to the eye may be but is not limited to the use of an isotonic solution.
1. A method of treating Streptococcus A infection of an upper respiratory tract, wherein the method comprises administering a composition comprising:
(a) an effective amount of lysin enzyme genetically coded for by a C1 bacteriophage, said lysin enzyme having the ability to digest a cell wall of Streptococcus A ; and
(b) a carrier suitable for delivering said lysin enzyme to a mouth, throat, or nasal passage, wherein said method provides a concentration from about 100 to about 500,000 active enzyme units per milliliter of fluid in the environment of said nasal or oral passage.
2. The method according to claim 1 , wherein said carrier is selected from the group consisting of candy, chewing gum, lozenge, troche, tablet, powder, aerosol, liquid and liquid spray.
3. The method according to claim 1 , wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.
4. The method according to claim 1 , wherein the buffer maintains the pH of the composition at the range between about 5.5 and about 7.5.
5. The method according to claim 1 , wherein said buffer comprises a reducing reagent.
6. The method according to claim 1 , wherein said reducing reagent is dithiothreitol.
7. The method according to claim 1 , wherein said buffer comprises a metal chelating reagent.
8. The method according to claim 1 , wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.
9. The method according to claim 1 , wherein said buffer is a citrate-phosphate buffer.
10. The method according to claim 1 , further comprising a bactericidal or bacteriostatic agent as a preservative.
11. The method according to claim 1 , wherein said lysin enzyme is lyophilized.
12. The method according to claim 1 , wherein said carrier further comprises a sweetener.
13. The method according claim 1 , comprising administering a concentration of about 100 to about 500,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passage.
14. The method according to claim 1 , comprising administering the concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passage.